Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC


In Partnership With:

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Although adjuvant therapy is currently utilized for patients who are at high risk of recurrence, there is important rationale behind giving therapy to patients prior to surgery, Ornstein explains. Neoadjuvant therapy can decrease tumor size, enabling easier resection and allowing additional nephron sparing to preserve as much healthy kidney tissue as possible, Ornstein says.

Additionally, it is theorized that neoadjuvant immunotherapy could produce better results for patients, Ornstein continues. Data from other tumor types suggest that immunotherapy before surgery can improve disease-free survival, compared with the adjuvant setting, Ornstein concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS